• Optain

  Participated · Series A · Sep 2025

  Optain Health offers a portable robotic retinal camera, integrated AI workflows, and teleophthalmology to enable rapid, non‑invasive screening for eye diseases and systemic risk (oculomics). Its platform detects diabetic retinopathy, glaucoma, age‑related macular degeneration, and assesses cardiovascular risk while delivering teleophthalmology grading in the U.S. The company was co‑created in 2023 by Aegis Ventures and builds on more than a decade of Australian R&D led by Professor Mingguang He. Optain is expanding deployments into primary care, optometry, and health systems with the goal of closing care gaps and improving outcomes with minimal specialist staffing. The company uses teleophthalmology services in the U.S.; its automated disease detection software is not for sale in the U.S. Optain is scaling globally with investments in Australian R&D to support expansion outside the U.S. Optain develops AI-enabled software and hardware that noninvasively diagnose eye and systemic health conditions in real time using photos of the eye. Its portable retinal camera and accompanying AI software enable clinicians to screen for more than 140 eye and systemic conditions at early stages. The company is led by CEO Jeff Dunkel and positions the eye as a gateway to monitor whole-person health. Optain's approach is based on over a decade of research by Professor Mingguang He of the University of Melbourne and the Centre for Eye Research Australia. The company traces its roots to Australian-founded Eyetelligence (launched in 2019), whose clinically validated and regulatory-approved AI products are commercialized across Australia, New Zealand, Europe, Japan and the Middle East. Optain intends to use recent seed funding to expand operations and development efforts.

No current team members are available.